Robbert J van Alphen
Overview
Explore the profile of Robbert J van Alphen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Darai A, Koeter T, van Erning F, van Alphen R, Verheul H, Verheij M, et al.
Colorectal Dis
. 2025 Mar;
27(3):e70054.
PMID: 40059308
Aim: Treatment of rectal cancer has improved significantly over the past decades. However, the role of adjuvant chemotherapy remains a matter of debate. The aim of this study is to...
2.
Bond M, Bolhuis K, Loosveld O, de Groot J, Droogendijk H, Helgason H, et al.
JAMA Oncol
. 2024 Nov;
11(1):36-45.
PMID: 39570583
Importance: In patients with colorectal cancer and unresectable liver-only metastases (CRLM), treatment with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) plus irinotecan (FOLFOXIRI) and bevacizumab vs FOLFOX/folinic acid, fluorouracil, and irinotecan...
3.
Guchelaar N, Buck S, van Doorn L, Hussaarts K, Sandberg Y, van der Padt-Pruijsten A, et al.
Clin Pharmacokinet
. 2024 Jul;
63(7):1037-1044.
PMID: 38951433
Background And Objectives: Trifluridine/tipiracil, registered for the treatment of patients with metastatic gastric and colorectal cancer, is a substrate and inhibitor for the organic cation transporter 2 (OCT2) and the...
4.
Bond M, Bolhuis K, Loosveld O, de Groot J, Droogendijk H, Helgason H, et al.
Lancet Oncol
. 2023 Jun;
24(7):757-771.
PMID: 37329889
Background: Patients with initially unresectable colorectal cancer liver metastases might qualify for local treatment with curative intent after reducing the tumour size by induction systemic treatment. We aimed to compare...
5.
van Rossum A, Mandjes I, van Werkhoven E, van Tinteren H, van Leeuwen-Stok A, Nederlof P, et al.
Breast Care (Basel)
. 2022 Jan;
16(6):598-606.
PMID: 35087363
Background: The addition of bevacizumab to chemotherapy conferred a modest progression-free survival (PFS) benefit in metastatic triple-negative breast cancer (mTNBC). However, no overall survival (OS) benefit has been reported. Also,...
6.
Braal C, Jager A, Oomen-de Hoop E, Westenberg J, Lommen K, de Bruijn P, et al.
Clin Pharmacokinet
. 2021 Nov;
61(4):527-537.
PMID: 34786650
Background: Endoxifen is the most important active metabolite of tamoxifen. Several retrospective studies have suggested a minimal or threshold endoxifen systemic concentration of 14-16 nM is required for a lower...
7.
Hussaarts K, Berger F, Binkhorst L, Oomen-de Hoop E, van Leeuwen R, van Alphen R, et al.
Pharm Res
. 2019 Dec;
37(1):7.
PMID: 31845095
Purpose: Antidepressants like the serotonin reuptake inhibitors (SRIs) are often used concomitantly with tamoxifen (e.g. for treatment of depression). This may lead to an additional prolongation of the QTc-interval, with...
8.
Hussaarts K, Hurkmans D, Oomen-de Hoop E, van Harten L, Berghuis S, van Alphen R, et al.
Cancers (Basel)
. 2019 Mar;
11(3).
PMID: 30909366
Tamoxifen is a prodrug that is primarily metabolized into the pharmacologically active metabolite endoxifen and eventually into inactive metabolites. The herb curcumin may increase endoxifen exposure by affecting phase II...
9.
Kwakman J, van Werkhoven E, Simkens L, van Rooijen J, van de Wouw Y, Ten Tije A, et al.
Clin Colorectal Cancer
. 2019 Feb;
18(2):e229-e230.
PMID: 30782413
No abstract available.
10.
Belderbos B, Hussaarts K, van Harten L, Oomen-de Hoop E, de Bruijn P, Hamberg P, et al.
Br J Clin Pharmacol
. 2019 Feb;
85(5):986-992.
PMID: 30737835
Aims: Docetaxel has been approved for the treatment of metastatic prostate cancer in combination with prednisone. Since prednisone is known to induce the cytochrome P450 iso-enzyme CYP3A4, which is the...